SGN-30

DRUG2 trials

Sponsors

Seagen Inc., National Cancer Institute (NCI)

Conditions

Anaplastic Large Cell LymphomaLarge Cell Lymphoma

Phase 2

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

CompletedNCT00099255

Seagen Inc.Large Cell Lymphoma

Start: 2004-09-30End: 2007-02-28Target: 40Updated: 2014-12-18

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

TerminatedNCT00365274

National Cancer Institute (NCI)Anaplastic Large Cell Lymphoma

Start: 2006-08-31End: 2010-05-31Updated: 2014-06-02